US60770K1079
© ACCESS Newswire
15.12.2025
MRNA
LISTED
NASDAQ
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)
News Preview
mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)mNEXSPIKE will be available in the European Union, subject to authorization by the European Commission CAMBRIDGE, MA / ACCESS Newswire / December 15, 2025 / Moderna, Inc. (NASDAQ:MRNA)...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
20.11.2025
MRNA
LISTED
NASDAQ
Moderna Secures $1.5 Billion Five-Year Credit Facility from Ares Management
News Preview
Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibilityCompany reiterates 2025 financial guidance provided on 3Q25 earnings call and targets cash breakeven by 2028 CAMBRIDGE, MA / ACCESS Newswire / November 20, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it has closed a five-year term loan...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
20.11.2025
MRNA
LISTED
NASDAQ
Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates
News Preview
Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026Expects to expand seasonal vaccine franchise from three to up to six approved products by 2028Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismera...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© ACCESS Newswire
19.11.2025
MRNA
LISTED
NASDAQ
Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities
News Preview
New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing networkMore than $140 million investment will create hundreds of highly skilled biomanufacturing jobs CAMBRIDGE, MA / ACCESS Newswire / November 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced the expansion of its U.S. manufacturing capab...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© ACCESS Newswire
18.11.2025
MRNA
LISTED
NASDAQ
Moderna to Present at Upcoming Piper Sandler's 37th Annual Healthcare Conference on December 2, 2025
News Preview
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / November 18, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference:Piper Sandler's 37th Annual Healthcare Conference, on Tuesday, December 2nd at 11:00am ETA live webcast of each of the presentation will be available under "Events and Pre...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
06.11.2025
MRNA
LISTED
NASDAQ
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates
News Preview
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51)Narrows 2025 projected revenue range to $1.6 - $2.0 billionImproves 2025 expected GAAP operating expenses by $0.7 billion to a range of $5.2 - $5.4 billionIncreases 2025 expected year-end cash balance by $0.5 billion - $1 billion to a range of $6.5...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
03.11.2025
MRNA
LISTED
NASDAQ
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma
News Preview
CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company's investigational mRNA-based T-cell engager (TCE) for participants with relapsed or refractory multiple myeloma (RRMM). The first dose was administered at SCRI Oncology...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
23.10.2025
MRNA
LISTED
NASDAQ
Moderna Named a Top Employer by Science for Eleventh Consecutive Year
News Preview
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2025 Top Employers Survey for the eleventh consecutive year. Moderna was recognized for its commitment to continuous innovation and a culture that r...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
23.10.2025
MRNA
LISTED
NASDAQ
Moderna to Host Investor Event - Analyst Day
News Preview
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025.The event will include presentations from management discussing Moderna's development and commercial strategy and key business considerations.A live webcas...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
22.10.2025
MRNA
LISTED
NASDAQ
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint
News Preview
Company to discontinue development of mRNA-1647 in congenital CMVCompany will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patientsCompany does not anticipate any impact to its 2025 financial guidance or its expectation of achieving breakeven in 2028CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, I...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
19.10.2025
MRNA
LISTED
NASDAQ
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025
News Preview
CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, October 19-22, 2025, in Atlanta, GA. The details of the presentations are as follows:Late-Breaking Oral...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
16.10.2025
MRNA
LISTED
NASDAQ
Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
News Preview
CAMBRIDGE, MA, MA / ACCESS Newswire / October 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 6, 2025 to report its third quarter 2025 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ACCESS Newswire
12.10.2025
MRNA
LISTED
NASDAQ
Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress
News Preview
mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial CAMBRIDGE, MA, MA / ACCESS Newswire / October 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that clinical, safety and translational data from its Phase 1/2 study evaluating mRNA-4359 in combination with pembrolizumab in checkpoint inhibitor-resistant/refractory(...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
24.09.2025
MRNA
LISTED
NASDAQ
Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK
News Preview
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK populationThe facility marks a cornerstone of Moderna's ten-year strategic partnership with the UK Government, designed to strengthen health resilience and drive economic growth CAM...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
23.09.2025
MRNA
LISTED
NASDAQ
Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans
News Preview
Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groupsBoth of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains CAMBRIDGE, MA / ACCESS Newswire / Septembe...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
19.09.2025
MRNA
LISTED
NASDAQ
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories
News Preview
CAMBRIDGE, MA / ACCESS Newswire / September 19, 2025 / Moderna announced today that the first mRNA vaccines fully manufactured in Canada are being shipped to provinces and territories. This milestone advances Canada's domestic vaccine production capacity and strengthens national health security."The delivery of the first made-in-Canada mRNA va...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
16.09.2025
MRNA
LISTED
NASDAQ
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans
News Preview
Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groupsClinical findings reinforce preclinical data supporting recent FDA approval of 2025-2026 formula of Spikevax CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) tod...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
02.09.2025
MRNA
LISTED
NASDAQ
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism
News Preview
CAMBRIDGE, MA / ACCESS Newswire / September 2, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that five abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 International Congress of Inborn Errors of Metabolism (ICIEM), which will be held September 2-6, 2025 in Kyoto, Japan, at the Kyoto Internation...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
27.08.2025
MRNA
LISTED
NASDAQ
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2
News Preview
CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications (sBLA) for the 2025-2026 formulas for Spikevax® and mNEXSPIKE®, targeting the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19.Th...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
22.08.2025
MRNA
LISTED
NASDAQ
Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
News Preview
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna announced today that Health Canada has authorized its updated COVID-19 mRNA vaccine, Spikevax®, targeting the SARS-CoV-2 LP.8.1 variant, for individuals aged six months and older. Moderna i...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
21.08.2025
MRNA
LISTED
NASDAQ
Moderna to Present at Upcoming Conferences in September 2025
News Preview
CAMBRIDGE, MA / ACCESS Newswire / August 21, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced its participation in the following upcoming investor conferences:Morgan Stanley's 23rd Annual Global Healthcare Conference, on Monday, September 8th at 10:00am ETBernstein Insights: Healthcare Leaders and Disruptors, on Thursday, September 25th at 10:30a...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
01.08.2025
MRNA
LISTED
NASDAQ
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
News Preview
Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13)Updates 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million reduction at the high end, primarily driven by timing of deliveries for contracted revenue into the first quarter of 2026Improves 2025 expected GAAP operating...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
01.08.2025
MRNA
LISTED
NASDAQ
UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
News Preview
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent.This decision affirms the High Court's initial ruling from July 2024 that the EP'949 patent is valid and infringed by Pfizer/BioNTech's COVID-19 vaccine, Comirnaty®, which...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
30.07.2025
MRNA
LISTED
NASDAQ
Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
News Preview
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the updated formulation of the COVID-19 vaccine Spikevax®, targeting the SARS-CoV-2 variant LP.8.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individua...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
28.07.2025
MRNA
LISTED
NASDAQ
Moderna Announces Data to be Presented at ESMO Congress 2025
News Preview
CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO) Congress, which will be held October 17-21, 2025 in Berlin, Germany. This includes a mini oral presen...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
25.07.2025
MRNA
LISTED
NASDAQ
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
News Preview
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision CAMBRIDGE, MA / ACCESS Newswire / July 25, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopte...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
30.06.2025
MRNA
LISTED
NASDAQ
Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
News Preview
mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older CAMBRIDGE, MA / ACCESS Newswire / June 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive results from a Phase 3 efficacy study (P304) evaluati...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
12.06.2025
MRNA
LISTED
NASDAQ
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
News Preview
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company's respiratory syncytial virus (RSV) vaccine, for the preve...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
11.06.2025
MRNA
LISTED
NASDAQ
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025
News Preview
CAMBRIDGE, MA / ACCESS Newswire / June 11, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor event:Barclays Speaking the Science Call Series, on Monday, June 16th at 10:00am ETA live webcast of this presentation will be available under "Events and Presentations" in the Investors secti...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
31.05.2025
MRNA
LISTED
NASDAQ
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
News Preview
mNEXSPIKE becomes Moderna's third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mNEXSPIKE® (mRNA-1283), a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years wit...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
28.05.2025
MRNA
LISTED
NASDAQ
Moderna Announces Update on Investigational Pandemic Influenza Program
News Preview
Phase 1/2 H5 avian flu vaccine study shows positive interim resultsCompany has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMBRIDGE, MA / ACCESS Newswire / May 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT0597...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
27.05.2025
MRNA
LISTED
NASDAQ
Moderna to Present at Upcoming Conferences in June 2025
News Preview
CAMBRIDGE, MA / ACCESS Newswire / May 27, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:Jefferies Global Health Care Conference, on Thursday, June 5th at 10:30am ETGoldman Sachs 46th Annual Global Healthcare Conference, on Wednesday, June 11th at 8:40am ETA live webcast of each...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
23.05.2025
MRNA
LISTED
NASDAQ
Moderna Files FDA Application for the LP.8.1 Targeting COVID-19 Vaccine
News Preview
CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 formula, targeting the SARS-CoV-2 variant LP.8.1. The submission is based on guidance from the U.S. FDA, which advised that COVID-19 vac...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
21.05.2025
MRNA
LISTED
NASDAQ
Moderna Provides Update on BLA Submission for Combination Vaccine Against Influenza and COVID-19
News Preview
CAMBRIDGE, MA / ACCESS Newswire / May 21, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced that in consultation with the U.S. Food and Drug Administration (FDA), the Company has voluntarily withdrawn the pending Biologics License Application (BLA) for mRNA-1083, its flu/COVID combination vaccine candidate for adults aged 50 years and older. The...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
08.05.2025
MRNA
LISTED
NASDAQ
Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025
News Preview
CAMBRIDGE, MA / ACCESS Newswire / May 8, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference:Bernstein's 41st Annual Strategic Decisions Conference (SDC), on Thursday, May 29th at 10:00am ETA live webcast of each of these presentations will be available under "Events and Presentat...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
01.05.2025
MRNA
LISTED
NASDAQ
Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates
News Preview
Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52)Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance of approximately $6 billionAnnounces reduction of $1.4 to $1.7 billion in estimated GAAP operating costs by 2027Advancing up to 10 products toward approv...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
10.04.2025
MRNA
LISTED
NASDAQ
Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
News Preview
CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to report its first quarter 2025 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentat...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
07.04.2025
MRNA
LISTED
NASDAQ
Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025
News Preview
CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), norovirus, and mpox, at the European Society of Clinical Microbiology and Infectious D...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
31.03.2025
MRNA
LISTED
NASDAQ
Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults
News Preview
CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to prevent lower respiratory tract disease caused by RSV infection in adults aged 60 years an...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
28.02.2025
MRNA
LISTED
NASDAQ
Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine
News Preview
mRESVIA® is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for active immunization for the prevention...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
25.02.2025
MRNA
LISTED
NASDAQ
Moderna to Present at Upcoming Conferences in March 2025
News Preview
CAMBRIDGE, MA / ACCESS Newswire / February 25, 2025 / Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences:TD Cowen 45th Annual Health Care Conference, on Wednesday, March 5th at 9:10am ETBarclays 27th Annual Global Healthcare Conference, on Tuesday, March 11th at 1:30pm ETA live webcast of...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
14.02.2025
MRNA
LISTED
NASDAQ
Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates
News Preview
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizingReports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28)Expects 2025 revenue range of $1.5 to 2.5 b...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
29.01.2025
MRNA
LISTED
NASDAQ
Moderna to Report Fourth Quarter and Full Year 2024 Financial Results on Friday, February 14, 2025
News Preview
CAMBRIDGE, MA / ACCESS Newswire / January 29, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 14, 2025 to report its fourth quarter and full year 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
24.01.2025
MRNA
LISTED
NASDAQ
Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union
News Preview
The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats CAMBRIDGE, MA / ACCESS Newswire / January 24, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in th...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
17.01.2025
MRNA
LISTED
NASDAQ
Moderna Announces Updates on Pandemic Influenza Program
News Preview
CAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The award was made through the Rapid Response Partnership Vehicle (RRPV) Consortium with funding from th...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
13.01.2025
MRNA
LISTED
NASDAQ
Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited)Updates 2025 expected revenue range to $1.5 to 2.5 billionExpects to reduce 2025 cash cost expenses by $1.0 billion with a plan for additional 2026 cost reductions of $0.5 billionUpdates 2025 expected ending cash balanc...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
25.11.2024
MRNA
LISTED
NASDAQ
Moderna to Present at Upcoming Conferences in December 2024
News Preview
CAMBRIDGE, MA / ACCESSWIRE / November 25, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:7th Annual Evercore ISI HealthCONx Conference, on Wednesday, December 4th at 1:20pm ETPiper Sandler 36th Annual Healthcare Conference, on Thursday, December 5th at 10:30am ETA live webcast of...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
12.11.2024
MRNA
LISTED
NASDAQ
Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year
News Preview
CAMBRIDGE, MA / ACCESSWIRE / November 12, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2025 Best Places to Work report based on the Company's reputation and commitment to innovation."We are honored to be recognized by BioSpace as the most desirable large employer in the life scien...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
08.11.2024
MRNA
LISTED
NASDAQ
Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
News Preview
mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringesCanada is the fourth jurisdiction to approve mRESVIA following approvals in the U.S., Europe, and QatarCAMBRIDGE, MA / ACCESSWIRE / November 8, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced Health Canad...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
07.11.2024
MRNA
LISTED
NASDAQ
Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
News Preview
Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 to $3.5 billionInitiated dosing in two pivotal Phase 3 trials to assess efficacy of investigational mRNA vaccines against norovirus and influenzaAnnou...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
31.10.2024
MRNA
LISTED
NASDAQ
Moderna to Present at Upcoming Conferences in November 2024
News Preview
CAMBRIDGE, MA / ACCESSWIRE / October 31, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences:Guggenheim's Inaugural Healthcare Innovation Conference, on Tuesday, November 12th at 10:00am ETUBS Global Healthcare Conference, on Wednesday, November 13th at 3:30pm PTJefferies London Healt...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
24.10.2024
MRNA
LISTED
NASDAQ
Moderna Named a Top Employer by Science for Tenth Consecutive Year
News Preview
CAMBRIDGE, MA / ACCESSWIRE / October 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2024 Top Employers Survey for the tenth consecutive year. Moderna was recognized for its commitment to continuous innovation, treating employees with res...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
17.10.2024
MRNA
LISTED
NASDAQ
Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
News Preview
CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 7, 2024 to report its third quarter 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Present...
Themefolio
Profiler
Peergroup
© BusinessWire
08.10.2024
MRNA
LISTED
NASDAQ
MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. (“Moderna” or “the Company”) (NASDAQ: MRNA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors...
Themefolio
Profiler
Peergroup
© BusinessWire
06.10.2024
MRNA
LISTED
NASDAQ
MRNA Deadline: Rosen Law Firm Urges Moderna, Inc. (NASDAQ: MRNA) Stockholders With Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024. Moderna describes itself as a “biotechnology company that discovers, develops, and commercializes messenger RNA (“mRNA”) t...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
02.10.2024
MRNA
LISTED
NASDAQ
Abbas Hussain Joins Moderna's Board of Directors
News Preview
Hussain brings more than 35 years of commercial leadership and operating experience in healthcare, most recently serving as CEO of Vifor PharmaAs former Global President of GSK, Pharmaceuticals and Vaccines, Hussain brings significant global vaccine commercialization experience in emerging and mature markets, along with significant Board of Directo...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
30.09.2024
MRNA
LISTED
NASDAQ
Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines
News Preview
CAMBRIDGE, MA and TAIPEI, TAIWAN / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Cenra Healthcare, the sales and marketing arm of Cenra Inc., today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Taiwan, including Moderna's COVID-19 va...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
30.09.2024
MRNA
LISTED
NASDAQ
Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
News Preview
CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized clinical trial evaluating the efficacy, safety, and immunogenicity of an investigational norovirus vaccine, mRNA-1403. Global recruitment for the Nova...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
17.09.2024
MRNA
LISTED
NASDAQ
Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
News Preview
SPIKEVAX® is the first updated COVID-19 vaccine authorized in Canada for 2024-2025, offering a timely solution to help protect Canadians this fall and winter season.Moderna will promptly begin delivery of updated COVID-19 vaccines to the Public Health Agency of Canada, so there is robust supply available in time for provincial and territorial...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
05.09.2024
MRNA
LISTED
NASDAQ
Ausschuss für Humanarzneimittel der EMA gibt positive Stellungnahme ab und empfiehlt Zulassung von Modernas COVID-19-mRNA-Impfstoff, der gegen die SARS-COV-2-Variante JN.1 gerichtet ist
News Preview
Moderna, Inc. (NASDAQ: MRNA) hat heute bekannt gegeben, dass der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur (EMA) eine positive Stellungnahme abgegeben hat, in welcher die Marktzulassung einer aktualisierten Formulierung des COVID-19-mRNA-Impfstoffs Spikevax, der auf die SARS-CoV-2-Variante JN.1 abzielt,...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
